The films of south India are now on a pedestal. Malayalam, Tamil, Telugu and to a lesser extent Kannada cinema have usurped the homogeneity of Hindi cinema in popular culture. There is a crisis of confidence—not stories or storytellers—in Hindi cinema, but it is dictated by box-office numbers and the industry's set ways.
That crisis exists in Tamil too. It is only Telugu that possesses some secret sauce for pan-Indianness, a concoction so repetitive it stands at the doorstep of saturation (Pushpa 2: The Rule is its latest dilution).
Yet, the south is routinely producing films the larger public yearns for. It is a mistake to put all of south Indian cinema in one box. The four industries have different financial structures, and the calibre of writers, directors, actors and stars wildly differ. 2024 was a strange year for many reasons in the south—characters crossed borders, an industry learned a lesson, and arthouse mingled with the mainstream.
THE TRAVELLING MALAYALAM CINEMA
Malayalam cinema has legs. In 2024, the cinema went beyond Kerala's borders. It began with the greatest swing of them all. Lijo Jose Pellissery's Malaikottai Vaaliban drops us into the middle of a desert with vivid colours and prizefights. An unnamed universe where Vaaliban's (Mohanlal) Malayalam blends with Rangapattinam Rangarani's (Sonalee Kulkarni) Tamil, a harmony as fluid and precise as the swordfights with a Portuguese army.
Esta historia es de la edición December 28, 2024 de Mint Kolkata.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición December 28, 2024 de Mint Kolkata.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Intel's grim lesson for Boeing: Sometimes Mr. Fix-It is too late
One day, fickle investors are applauding business-school alumni for paying big dividends and slashing costs. The next, they're demanding that engineers take over to make up for lost innovation.
Beijing Pushes to Use China-Made Chips in Its Electric Vehicles
Not long ago, almost all the chips in Chinese cars relied on manufacturing by foreign firms
Will the Guardrails of US Democracy Hold?
America's democratic institutions withstood, if only barely, Donald Trump's first presidency, but will they do so again?
RIL's acquisitions: $13 bn spent in 5 yrs
Billionaire Mukesh Ambani's Reliance Industries Ltd (RIL) has spent $13 billion on acquisitions in the past five years across new energy, telecom, retail and media business to script a pivot away from core oil and petrochemicals business to clean energy and consumer-facing verticals.
Sebi introduces MF Lite framework
Index and exchange-traded funds (ETFs) to schemes sponsored by private equity funds will be eligible to be covered under the MF Lite framework on meeting certain conditions as the market regulator aims to simplify the operations of passively managed mutual funds.
Gold Heads for Biggest Gain Since 2010 in Mixed Year for Metals
Gold is heading for its biggest gain in 14 years, with a 27% advance fueled by US monetary easing, sustained geopolitical risks and a wave of purchases by central banks.
Interest on PPF, NSC unchanged
The government on Tuesday left the interest rates unchanged on various small savings schemes, including Public Provident Fund (PPF) and National Savings Certificate (NSC), for the fourth straight quarter beginning 1 January 2023 and ending 31 March 2025.
Rupee declines to record closing low
The rupee declined to a record closing low for the sixth consecutive session on Tuesday, weighed down by a decline in most Asian currencies alongside expectations that it is headed for more losses in 2025.
NaBFID invests ₹745 cr in NDR InvIT
The National Bank for Financing Infrastructure and Development (NaBFID) has invested ₹745 crore in long-term bonds issued by NDR InvIT, the company said on Tuesday.
Drugmaker Anthem files for IPO
Indian contract drugmaker Anthem Biosciences filed for a ₹33.95 billion ($397 million) initial public offering (IPO), draft papers showed on Tuesday, at the fag end of what has been a red-hot year for companies listing on the stock market.